Search Within

Shanu Modi

Formats
  1. Meeting Abstract (150)
  2. Journal Article (99)
  3. Review (11)
  4. Correspondence (2)
  5. Editorial (2)
  6. Research Letter (1)
Groups
  1. Breast Medicine Service (265)
  2. Department of Medicine (265)
  3. Solid Tumor Oncology Division (265)
  4. Survivorship Research (113)
  5. GSK Faculty (104)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (88)

More Groups

People
  1. Clifford Hudis (79)
  2. Larry Norton (53)
  3. Sarat Chandarlapaty (49)
  4. Sujata Patil (44)
  5. Chau Dang (41)
  6. Komal Jhaveri (34)

More People

Years
  1. 2025 (5)
  2. 2024 (23)
  3. 2023 (15)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (21)

More Years

Publications
  1. Journal of Clinical Oncology (65)
  2. Cancer Research (50)
  3. Annals of Oncology (27)
  4. Breast Cancer Research and Treatment (14)
  5. Clinical Cancer Research (10)
  6. Clinical Breast Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (66)
  2. American Association for Cancer Research (64)
  3. Oxford University Press (33)
  4. Elsevier Inc. (19)
  5. Springer (18)
  6. Nature Publishing Group (13)

More Publishers

Results (265)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: A dose-expansion, phase 1 study
    Journal Article

    Tamura, K.; Tsurutani, J.; Takahashi, S.; Iwata, H.; Krop, I. E.; Redfern, C.; Sagara, Y.; Doi, T.; Park, H.; Murthy, R. K.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study
    Journal Article

    Shitara, K.; Iwata, H.; Takahashi, S.; Tamura, K.; Park, H.; Modi, S.; Tsurutani, J.; Kadowaki, S.; Yamaguchi, K.; Iwasa, S.; more...
    Lancet Oncology (2019)

    Fulltext@MSK | Save
  • Chaperome heterogeneity and its implications for cancer study and treatment
    Review

    Wang, T.; Rodina, A.; Dunphy, M. P.; Corben, A.; Modi, S.; Guzman, M. L.; Gewirth, D. T.; Chiosis, G.
    Journal of Biological Chemistry (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts
    Meeting Abstract

    Iwata, H.; Tamura, K.; Doi, T.; Tsurutani, J.; Modi, S.; Park, H.; Krop, I. E.; Sagara, Y.; Redfern, C. H.; Murthy, R. K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1
    Meeting Abstract

    Baselga, J.; Tamura, K.; Yamashita, T.; Modi, S.; Tokunaga, E.; Ito, Y.; Iwata, H.; Charif, M.; Lee, C. C.; Sugihara, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2-advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane
    Meeting Abstract

    Bardia, A.; Modi, S.; Cortes, J.; Campone, M.; Dirix, L.; Ma, B.; Beck, J. T.; Chaves, J.; Weise, A.; Vuky, J.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
    Meeting Abstract

    Yoshino, T.; Iwata, H.; Tamura, K.; Takahashi, S.; Redfern, C.; Modi, S.; Doi, T.; Kawakami, H.; Taniguchi, H.; Takashima, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
    Meeting Abstract

    Specht, J.; Pusztai, L.; Forero-Torres, A.; Mita, M.; Weise, A.; Krop, I.; Grosse-Wilde, A.; Wang, Z.; Li, M.; Hengel, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Updated results of phase 1 study of DS-8201a in HER2-expressing or -mutated advanced non-small-cell lung cancer
    Meeting Abstract

    Tsurutani, J.; Park, H.; Doi, T.; Modi, S.; Takahashi, S.; Nakagawa, K.; Krop, I.; Waqar, S.; Yoh, K.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save